Sequencing of the human genome and the evidence correlating specific genetic variations to diseases have opened up the potential of genomics to more effective and less harmful interventions of human diseases. A wealth of pharmacogenomics knowledge is in place for the practice of precision medicine. However, this knowledge is not fully realized in clinical practice. One reason for this impasse is the lack of in-depth understanding of the potential of pharmacogenomics among the healthcare professionals. Pharmacists are the point-of-care providers and are expected to advise clinicians on matters relating to the implementation of pharmacogenomics in patient care. However, current pharmacogenomics instruction in pharmacy schools fails to produce pharmacists with the required knowledge or practical training in this discipline. In this perspective, we provide several strategies to overcome limitations faced by pharmacy schools. Once implemented, pharmacy schools will produce precision medicine-ready pharmacists.
and 1991. After prescribed inves tigations, the patients were randomly allocated in groups of 3 to 3 treatment regimens, namely: 1, clofazimine 50 mg daily and 300 mg once in 4 weeks + dapsone 100 mg daily (AA); 2, (AA)+ofioxacin 400 mg daily (BB); and 3, (AA)+ofioxacin 800 mg daily (CC). The drugs were administered for 56 days continuously under supervision. Sequential biopsy results on day 0, 7, 14, 28 and 56 in normal mouse footpad revealed no growth by day 28 and 56 in all patients treated with CC and BB regimens, respectively. Calculation of the proportion of viable My cobacterium leprae through analysis of median infectious dose (ID so) showed significant differences on day 7 in the percentage of kill between the ofioxacin-containing regimens and the other. Moderate to marked clinical improvement has been observed in a significantly higher proportion of patients treated with ofioxacin-containing regimens. All the 3 regimens were well tolerated. No severe complications or side-effects to the drugs were noticed with any of the regimens that required any suspension of treatment or the administration of steroids. Addition of ofloxacin to the standard WHO recom mended MDT regimen for multi bacillary patients may reduce the present duration of therapy. Ofioxacin may also be considered as an alternative drug in rifampicin-resistant cases or where rifampicin is contraindicated. The identification of bactericidal chemotherapeutic agents and the determination of their appropriate dosages and duration with and without other drugs is a priority in the quest for leprosy control, in the absence of a primary preventive measure such as an effective vaccine. There are only 4 bactericidal drugs (rifampicin, dapsone, clofazimine and thiomides) which are recommended for combined drug regimens, l and are widely used in the treatment of lepromatous leprosy. Each of the last 3 drugs, besides being weakly
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.